{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:14:03Z","timestamp":1778876043688,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ebiom.2026.106271","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:50:11Z","timestamp":1777600211000},"page":"106271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector\u2013based vaccines"],"prefix":"10.1016","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9294-6586","authenticated-orcid":false,"given":"Nina","family":"Hertoghs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen","family":"Tolboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"van Heesbeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nynke","family":"Ligtenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Merrall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariska","family":"van Rosmalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludo","family":"Lavreys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaike","family":"Maat-Ligthart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea","family":"McLean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Luhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ebiom.2026.106271_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: from basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"40","key":"10.1016\/j.ebiom.2026.106271_bib2","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1016\/j.vaccine.2015.03.072","article-title":"Systems vaccinology: enabling rational vaccine design with systems biological approaches","volume":"33","author":"Hagan","year":"2015","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106271_bib3","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41590-022-01328-6","article-title":"Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses","volume":"23","author":"Hagan","year":"2022","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106271_bib4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41597-022-01714-7","article-title":"The Immune Signatures data resource, a compendium of systems vaccinology datasets","volume":"9","author":"Diray-Arce","year":"2022","journal-title":"Sci Data"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106271_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ni.2789","article-title":"Molecular signatures of antibody responses derived from a systems biology study of five human vaccines","volume":"15","author":"Li","year":"2014","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.ebiom.2026.106271_bib6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/ni.2067","article-title":"Systems biology of vaccination for seasonal influenza in humans","volume":"12","author":"Nakaya","year":"2011","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106271_bib7","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106271_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106271_bib9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1152\/advan.00058.2013","article-title":"Pattern recognition receptors in innate immunity, host defense, and immunopathology","volume":"37","author":"Suresh","year":"2013","journal-title":"Adv Physiol Educ"},{"issue":"19","key":"10.1016\/j.ebiom.2026.106271_bib10","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1016\/j.vaccine.2024.03.079","article-title":"Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: results of a randomized, double-blind, phase 2 trial","volume":"42","author":"Le Gars","year":"2024","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106271_bib23","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1473-3099(24)00226-3","article-title":"Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study","volume":"24","author":"Falsey","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"26","key":"10.1016\/j.ebiom.2026.106271_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126273","article-title":"Immunogenicity and safety of different dose levels of Ad26.RSV.preF\/RSV preF protein vaccine in adults aged 60 years and older: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"42","author":"van Heesbeen","year":"2024","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.ebiom.2026.106271_bib36","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26\u2013 and modified vaccinia Ankara\u2013vectored Ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106271_bib37","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/infdis\/jiaa193","article-title":"Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged \u226560 years","volume":"222","author":"Williams","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ebiom.2026.106271_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"19","key":"10.1016\/j.ebiom.2026.106271_bib11","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106271_bib12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2207566","article-title":"Efficacy and safety of an Ad26.RSV.preF\u2013RSV preF protein vaccine in older adults","volume":"388","author":"Falsey","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106271_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215457","article-title":"Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples","volume":"14","author":"Rudge","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ebiom.2026.106271_bib15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s11239-021-02626-w","article-title":"A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines","volume":"53","author":"Elberry","year":"2022","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106271_bib35","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1038\/s41467-021-24584-w","article-title":"Development of a fixed module repertoire for the analysis and interpretation of blood transcriptome data","volume":"12","author":"Altman","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ebiom.2026.106271_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled phase II clinical trial in Africa","volume":"18","author":"Barry","year":"2021","journal-title":"PLoS Med"},{"issue":"12","key":"10.1016\/j.ebiom.2026.106271_bib16","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41590-022-01329-5","article-title":"Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination","volume":"23","author":"Fourati","year":"2022","journal-title":"Nat Immunol"},{"issue":"13","key":"10.1016\/j.ebiom.2026.106271_bib17","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.3390\/ijms25137095","article-title":"Deciphering immune responses to immunization via transcriptional analysis: a narrative review of the current evidence towards personalized vaccination strategies","volume":"25","author":"Papadatou","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106271_bib18","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1038\/s41467-024-47463-6","article-title":"Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease","volume":"15","author":"Drury","year":"2024","journal-title":"Nat Commun"},{"issue":"23","key":"10.1016\/j.ebiom.2026.106271_bib19","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ebiom.2026.106271_bib20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S1473-3099(24)00058-6","volume":"24","author":"Lariviere","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106271_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.ebiom.2026.106271_bib22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/infdis\/jiac142","article-title":"Impact of preexisting anti-adenovirus 26 humoral immunity on immunogenicity of the Ad26.COV2.S coronavirus disease 2019 vaccine","volume":"226","author":"Le Gars","year":"2022","journal-title":"J Infect Dis"},{"issue":"Pt 1","key":"10.1016\/j.ebiom.2026.106271_bib25","article-title":"Safety and immunogenicity of the Ad26\/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: a phase 3, randomized, controlled, immunobridging trial","volume":"43","author":"Jastorff","year":"2025","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ebiom.2026.106271_bib26","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.immuni.2016.04.019","article-title":"The TNF receptor superfamily in co-stimulating and co-inhibitory responses","volume":"44","author":"Ward-Kavanagh","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106271_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1021\/ar800114w","article-title":"Keeping uracil out of DNA: physiological role, structure and catalytic mechanism of dUTPases","volume":"42","author":"Vertessy","year":"2009","journal-title":"Acc Chem Res"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106271_bib28","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1038\/s41598-017-06206-y","article-title":"Differential control of dNTP biosynthesis and genome integrity maintenance by the dUTPase superfamily enzymes","volume":"7","author":"Hirmondo","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ebiom.2026.106271_bib29","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S2666-5247(21)00235-4","article-title":"Transcriptomic signatures induced by the Ebola virus vaccine rVSV\u0394G-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study","volume":"3","author":"Vianello","year":"2022","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.ebiom.2026.106271_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41541-022-00583-w","article-title":"Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination","volume":"7","author":"Aydillo","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"20","key":"10.1016\/j.ebiom.2026.106271_bib31","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.vaccine.2021.04.006","article-title":"The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: a phase I randomized, double-blinded, controlled trial","volume":"39","author":"Pu","year":"2021","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.ebiom.2026.106271_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113101","article-title":"Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV\/MVA-BN-Filo","volume":"42","author":"Blengio","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.ebiom.2026.106271_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1500615","article-title":"MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity","volume":"15","author":"Grewe","year":"2024","journal-title":"Front Immunol"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426001532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396426001532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:39:43Z","timestamp":1778873983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396426001532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"alternative-id":["S2352396426001532"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106271","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, observer-blind, phase 1 study of immune responses to three human adenovirus type 26 vector\u2013based vaccines","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2026.106271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106271"}}